The drug has the active ingredient enoxaparin sodium which has anticoagulant effects and several other benefits. To ensure effective treatment, patients need to strictly follow the instructions of the doctor, pharmacist advising on the use of the drug.

Venous thromboembolism occurs in approximately 20% of pancreatic cancer patients, resulting in significant morbidity, mortality, and healthcare costs. The management of venous thromboembolism is particularly challenging in these patients. Adequate selection of the most appropriate anticoagulant for each patient according to current international guidelines is warranted to overcome the treatment challenges.